Additional file 2: List of excluded studies

Studies by each reason for exclusion.

Reason for exclusion, population (n=3)


Reason for exclusion, intervention (n=127)


MANDRIK, O., KNIES, S., GOLUBOVSKA, O., DUDA, O., DUDAR, L., FEDORCHENKO, S., ZALISKA, O. & HANS SEVERENS, J. L. 2015. Cost comparison


Reason for exclusion, outcome (n=4)


Reason for exclusion, study design (n=32)


**Reason for exclusion, abstract only** (n=121)

AHMED, A., GORDON, S. C., SAAB, S. & YOUNOSSI, Z. 2014. Evaluation of the health outcomes for ledipasvir/sofosbuvir in early vs. Delayed treatment according to fibrosis stage of patients with chronic hepatitis C virus (HCV) genotype 1 infection: Results from a decision-analytic markov model. Hepatology, 60, 1041A.


combination treatment in the management of chronic hepatitis c virus infection for
treatment-naive patients with IL28B genotype CC. Gastroenterology, 142, S173.


SILVA, M., FELIX, J., FERREIRA, D., VANDEWALLE, B., GUERRA, I., CURE, S., ALDIR, I., CARVALHO, A., MACEDO, G., MARINHO, R. T., PEDROTO, I. &


YOUNOSSI, Z., SAAB, S., AHMED, A. & GORDON, S. C. 2014. A decision-analytic markov model to evaluate the health outcomes of ledipasvir/sofosbuvir (LDV/SOF) for patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection. Hepatology, 60, 1043A-1043A.


Reason for exclusion, language (n=14)


Reason for exclusion, review (n=1)

Reason for exclusion, duplicate (n=1)

Reason for exclusion, unobtainable (n=2)


Reason for exclusion, no usable data (n=2)